Femasys Achieves Australian and New Zealand Regulatory Approvals for FemaSeed(R) for First-Line Infertility Treatment and FemVue Diagnostic
(NASDAQ:FEMY), — Milestone expands global reach and reinforces commitment to accessible, first-line infertility solutions — ATLANTA, July 01, 2025 (GLOBE NEWSWIRE) — Femasys, Inc., (Nasdaq: FEMY), a leading biomedical innovator addressing significant unmet needs in women's health worldwide, with a broad portfolio of disruptive, accessible, in-office therapeutic and diagnostic products announces the achievement of regulatory […]